Filing Details

Accession Number:
0001415889-24-028001
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-12-02 17:18:40
Reporting Period:
2024-11-27
Accepted Time:
2024-12-02 17:18:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1672619 Enliven Therapeutics Inc. ELVN Pharmaceutical Preparations (2834) 811523849
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1882764 Benjamin Hohl C/O Enliven Therapeutics, Inc.
6200 Lookout Road
Boulder CO 80301
Chief Financial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-11-27 5,250 $2.48 5,250 No 4 M Direct
Common Stock Disposition 2024-11-27 4,250 $24.78 1,000 No 4 S Direct
Common Stock Disposition 2024-11-27 1,000 $25.38 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2024-11-27 5,250 $0.00 5,250 $2.48
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
168,556 2031-08-02 No 4 M Direct
Footnotes
  1. The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
  2. This transaction was executed in multiple trades at prices ranging from $24.25 to $25.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  3. This transaction was executed in multiple trades at prices ranging from $25.26 to $25.41. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  4. The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter.